World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
44
Citations
9723
World Ranking
19230
National Ranking
440

Overview

Daniel Podzamczer is affiliated with Bellvitge University Hospital in Spain and has contributed extensively to medical research, particularly in the field of infectious diseases. Their research primarily addresses HIV/AIDS drug development, treatment, and related health complications.

The main fields of study covered by their work include:

  • Medicine
  • Immunology and Microbiology

Within these fields, the subfields of particular focus are:

  • Infectious Diseases
  • Virology
  • Emergency Medicine
  • Epidemiology
  • Oncology

The topics most frequently investigated by Daniel Podzamczer are:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV/AIDS Research and Interventions
  • Viral-associated cancers and disorders
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Lipoproteins and Cardiovascular Health

Their recent significant publications include:

  • Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials (2020), The Lancet HIV
  • Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study (2021), The Lancet HIV
  • Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study (2021), Open Forum Infectious Diseases
  • Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial (2021), The Lancet HIV
  • Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials (2020), UNC Libraries

Frequent co-authors collaborating with Daniel Podzamczer include:

  • Estebán Martínez
  • María Saumoy
  • Peré Domingo
  • Mar Masiá
  • Juan Tiraboschi

They have published in several journals and venues, notably:

  • Journal of Antimicrobial Chemotherapy
  • Open Forum Infectious Diseases
  • The Lancet HIV
  • SSRN Electronic Journal
  • Journal of Pharmaceutical and Biomedical Analysis

Best Publications

  • Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

    Alison J Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

    Francois Raffi;Anita Rachlis;Hans-Jürgen Stellbrink;W David Hardy

  • Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

    David A. Margolis;Juan Gonzalez-Garcia;Hans Jürgen Stellbrink;Joseph J. Eron

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.

    J. Berenguer;P. Ryan;J. Rodríguez-Baño;I. Jarrín

  • Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.

    Frank A Post;Graeme J Moyle;Hans Jürgen Stellbrink;Pere Domingo

  • A prospective study of the risk of tuberculosis among HIV-infected patients.

    A Guelar;J M Gatell;J Verdejo;D Podzamczer

  • Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.

    Sharon Walmsley;Axel Baumgarten;Juan Berenguer;Franco Felizarta

  • Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

    Jean-Michel Molina;Douglas Ward;Indira Brar;Anthony Mills

  • Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

    José R Arribas;Pierre-Marie Girard;Roland Landman;Judit Pich

  • Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

    Samir K. Gupta;Frank A. Post;José R. Arribas;Joseph J. Eron

  • Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

    Jing Yuan;Sheng Guo;David Hall;Anna M Cammett

  • Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

    Jean-Michel Molina;Kathleen Squires;Paul E Sax;Pedro Cahn

  • A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.

    Margaret A. Johnson;Joseph C. Gathe;Daniel Podzamczer;Jean-Michel Molina

  • Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.

    Daniel Podzamczer;Albert Salazar;Josep Jimenez;Ezequiel Consiglio

  • Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

    Richard B. Pollard;Jürgen K. Rockstroh;Giuseppe Pantaleo;David M. Asmuth

  • Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.

    Luz Martin-Carbonero;Ana Barrios;Pere Saballs;Guillem Sirera

  • Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

    Vicente Soriano;Keikawus Arasteh;Horacio Migrone;Thomas Lutz

  • Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).

    Jesús Rodríguez-Baño;Jerónimo Pachón;Jordi Carratalà;Pablo Ryan

Frequent Co-Authors

Pere Domingo
Pere Domingo Autonomous University of Barcelona
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
Hernando Knobel
Hernando Knobel Autonomous University of Barcelona
Juan Berenguer
Juan Berenguer Hospital General Universitario Gregorio Marañón
José M. Gatell
José M. Gatell University of Barcelona
José M. Miró
José M. Miró University of Barcelona
Santiago Moreno
Santiago Moreno Hospital Universitario Ramón y Cajal
Chloe Orkin
Chloe Orkin Queen Mary University of London
Federico Pulido
Federico Pulido Complutense University of Madrid

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry in the USA opens the door to a wide array of advanced online degrees and career options in healthcare and science. Students can seamlessly extend their education into specialized graduate or professional programs to boost their employability and impact in growing fields.

Those interested in healthcare management may consider enrolling in the top online mha programs that are cahme accredited, which deliver industry-recognized credentials for future healthcare leaders. If you are seeking a clinical doctorate with more flexibility, look into a dnp program without clinical hours, designed for working professionals seeking leadership roles in nursing.

Ambitious students can also advance into online doctoral programs healthcare administration, combining scientific knowledge with executive skills for senior positions in the healthcare sector. Pharmacology enthusiasts may pursue online pharmd programs to transition into high-demand pharmacy roles without attending traditional campus classes.

These related online degrees support a wide variety of career pathways and are ideal for science graduates looking to deepen their expertise, specialize, or move into healthcare leadership and policy.

Best Scientists Citing Daniel Podzamczer

Trending Scientists